ADDF and Science Exchange Launch ADDF ACCESS to Advance Research


New “CRO Finder” Connects Scientists with Specialized Resources

$2.6 Million in New Grants Spurs Innovation


We announce 10 new grants totaling over $2.6 million to drive promising new approaches to treating and diagnosing Alzheimer’s and related dementias.

Tad Smith & Sotheby’s Honored at Connoisseur’s Dinner


11th annual gala raises $2.5 million for lifesaving Alzheimer's treatments

Author Sally Quinn Honored at Our Great Ladies Luncheon, Hosted by Judy Woodruff


We raised over $350,000 for life-saving research at our Seventh Annual Great Ladies Luncheon & Fashion Show at the Ritz-Carlton Washington, D.C., which honored author Sally for her work in the fight against Alzheimer’s. 

ADDF Invests $300,000 to Support Phase 2 Clinical Trial of Epigenetic Therapy


A new investment of $300,000 in Oryzon Genomics continues our support of its groundbreaking epigenetic drug ORY-2001.

ADDF-Funded Scientists Discover Two Repurposed Drugs With Promise for Alzheimer’s and FTD


A team of scientists from the Medical Research Council (MRC) in the UK have found two drugs, which block brain cell death and prevent neurodegeneration in preclinical studies. Their findings were published today in Brain.

ADDF Funding Advances M3 Biotechnology Toward Clinical Trials


Our new investment in M3 Biotechnology is advancing its drug program toward clinical trials

$4 Million in New Grants Support Several First-in-Class Dementia Treatments


We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.

ADDF An Official Charity Partner of the 2017 TCS New York City Marathon


We have been chosen as Official Charity Partner of the TCS New York City Marathon for the third year. The race will take place on Sunday, November 5, 2017.

Expanded Partnership Increases Support for Drug Discovery


ADDF and Harrington Institute increase funding and resources for promising Alzheimer’s drug discovery programs.